BioCentury | Aug 1, 2020
Product Development

July 31 Quick Takes: FDA approves MorphoSys’ tafasitamab; Truvian, AbbVie, Boehringer, Lilly, Alector, Henlius-Accord, Ascletis, Roche, Merck

MorphoSys follows Kress’ first big deal with U.S. approval FDA granted accelerated approval to Monjuvi tafasitamab-cxix from MorphoSys AG (Xetra:MOR; NASDAQ:MOR) and Incyte Corp. (NASDAQ:INCY) in combination with lenalidomide to treat patients with relapsed or...
BioCentury | May 8, 2020
Product Development

Japanese approval for Gilead’s remdesivir

Less than a week after FDA granted Emergency Use Authorization to Gilead’s COVID-19 therapy remdesivir, Japan approved the antiviral as Veklury. Separately, a global plasma coalition sealed a deal with NIH, and three Chinese biotechs...
BC Extra | Dec 13, 2019
Financial News

First day gains for Alphamab Oncology reflect Hong Kong exchange’s growing momentum

Double digit gains by Alphamab Oncology are the latest sign that Hong Kong’s biotech chapter has shrugged off mid-year doldrums and uncertainty caused by ongoing protests. Alphamab Oncology Ltd. (HKEX:9966) rose HK$3.30 (32%) to HK$13.50...
BC Extra | Dec 11, 2019
Financial News

Local demand high for Alphamab Oncology’s Hong Kong IPO

Local investors secured additional shares as Alphamab Oncology Ltd. (HKEX:9966) priced its IPO on the Hong Kong stock exchange Wednesday in a deal that raised HK$1.8 billion ($233.8 million) and valued the company at HK$9.1...
BC Extra | Oct 28, 2019
Financial News

After Hong Kong IPO lull, local demand lifts Ascentage offering

Robust local demand helped Ascentage to price its IPO at the top of its proposed range and its shares to rise out of the gate in the second offering after a four-month lapse in listings...
BioCentury | Oct 4, 2019

Biotechs likely to flood IPO market ahead of 2020 election

Buysiders and bankers expect a flood of IPOs and a stock picker's market in 4Q19 amid a continued run of sector underperformance that is only expected to get worse in 2020. As macro pressures continue...
BC Extra | Sep 18, 2019
Financial News

Hong Kong’s first IPO in months values Shanghai Henlius at $3.4B

Amid market concerns due to recent Hong Kong protests, Shanghai Henlius became the first company to list on the exchange’s biotech chapter in four months Wednesday, raising HK$3.2 billion ($409.9 million) in an IPO that...
BC Extra | Sep 13, 2019
Financial News

Sept. 12 Financial Quick Takes: IPOs from 10x, SpringWorks; plus Shanghai Henlius, Fate and more

Big gain for 10x after upsized IPO prices above range  Single-cell analytics company 10x Genomics Inc. (NASDAQ:TXG) gained $13.75 (35%) to $52.75 in its first day of trading after raising $390 million in its IPO....
BioCentury | Aug 16, 2019
Product Development

China’s biosimilars in fast lane

Though coming from behind, China is cracking the seal on its biosimilar market and may even be poised to over-take the U.S. and Europe in less than a decade. On February 22, 2019, China’s National...
BC Extra | Jul 9, 2019
Financial News

July 9 Financial Quick Takes: ADC tops off megaround with $27M; plus Genmab, GNS, StemRIM and more

ADC closes expanded E round at $303M   ADC Therapeutics S.A. (Lausanne, Switzerland) raised an additional $27 million in its expanded series E round, which closed at $303 million. In June, the developer of antibody-drug...
Items per page:
1 - 10 of 68